There is an increasing evidence that SGLT2 inhibition may reduce the growth of carcinomas that express SGLT2, including breast (Zhou et al. 2020), cervical (Xie et al. 2020), hepatocellular (Shiba et al. 2018), prostate, and lung carcinomas (Villani et al. 2016). This evidence concerns the gene SLC5A2 and carcinoma.